Bristol Myers Squibb shares positive arlo-cel trial data

Bristol Myers Squibb announced positive Phase 2 results on September 8 from its registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel, also known as arlo-cel. The study tested adult patients with quadruple-class exposed relapsed and refractory multiple myeloma who received three or more prior lines of therapy. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful overall response rate alongside strong complete response rates. The safety profile remained consistent with existing CAR T and GPRC5D-targeting therapies.

The clinical readout supports the drugmaker's strategy to expand its Growth Portfolio as older drugs face generic erosion. In the second quarter of 2026, total revenue rose 6% to $13.0 billion. Growth Portfolio revenue climbed 15% to $7.6 billion, lifted by drugs including Breyanzi, Opdivo, and Camzyos. Meanwhile, Legacy Portfolio revenue fell 4% to $5.4 billion due to generic competition.

The company posted $4.2 billion in second-quarter non-GAAP net income, while research and development spending climbed 15% to $3.0 billion. Strong operational performance prompted management to lift full-year 2026 revenue guidance to between $49.0 billion and $50.0 billion, with projected non-GAAP earnings per share between $6.75 and $7.00. Full-year operating expenses are projected to reach $16.5 billion.

Bristol Myers Squibb continues to manage execution challenges alongside the trial progress. Non-GAAP gross margin contracted from 72.6% to 71.4% because of shifts in product mix. Elevated balance-sheet leverage also narrows financial flexibility as the company works to bring arlo-cel through regulatory approvals and commercial manufacturing.